tbuckley/cabot-search huggingface dataset:
PARIS
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHEIROPOMPHOLYX
Authors: Arthur Whitfield
Journal: British Journal of Dermatology (1934)

Journal Article CHEIROPOMPHOLYX Get access Arthur Whitfield Arthur Whitfield Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 46, Issue 12, 1 December 1934, Page 552, https://doi.org/10.1111/j.1365-2133.1934.tb09775.x Published: 01 December 1934
A CASE OF AN ABNORMAL GROWTH OF THE UPPER EXTREMITY
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
Authors: Thomas H. Cartwright, Aimee Ginsburg Arlen, Lalan S. Wilfong, Robyn K. Harrell, J. Russell Hoverman, Roy A. Beveridge
Journal: Journal of Clinical Oncology (2013)

6607 Background: Pancreatic cancer (PC) is the fourth leading cause of death in the United States. It is estimated that 45,220 patients will be diagnosed in 2013 and 38,460 will die (Siegel, CA Cancer J Clin 2013). Gemcitabine has long been the standard of care chemotherapy. Recent advances in treatment created a combination regimen (oxaliplatin, irinotecan, leucovorin, fluorouracil [FOLFIRINOX]) for patients with good Karnofsky performance status (PS) (Conroy, NEJM 2011). This retrospective analysis was conducted as an update to results reported at ASCO 2012 (Ginsburg Arlen, JCO 2012) to evaluate characteristics and overall survival (OS) of patients receiving FOLFIRINOX and gemcitabine-based treatments in a large outpatient community setting. This is the largest study describing FOLFIRINOX patients to date. Methods: Patients with advanced PC treated within The US Oncology Network entered into the iKnowMed (iKM) database between June 2010 and November 2012 were included. Patterns of treatment were characterized by the median age at diagnosis, sex, PS, and first-line metastatic chemotherapy prescribed. The primary endpoints of the analysis were OS and uptake of FOLFIRINOX within the network. Results: Compared to ASCO 2012 results, 1,000 additional patients were identified in iKM. Of the 1,714 total patients, 24% received FOLFIRINOX (up from 13% in 2012) and 76% gemcitabine-based therapy (87% in 2012). Increased utilization of FOLFIRINOX for patients with good PS began in June 2010. For all patients (55% male), the median age at diagnosis was 67 years and the majority (85%) had a PS of 70% or greater. The OS was significantly longer for FOLFIRINOX (9.6 mos) versus gemcitabine (6.3 mos) (p&lt;0.0001). This held true for PS of 70% or greater patient given FOLFIRINOX (9.6 mos) versus gemcitabine (7 mos) (p&lt;0.0001). Conclusions: Utilization of FOLFIRINOX has continued to expand after the publication of phase III trials. Our data in a community setting supports a survival advantage for FOLFIRINOX. Although the magnitude of benefit may be smaller in the community, we agree that FOLFIRINOX should become a standard of care for good PS patients.
Bioethics
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic Kidney Disease
Authors: Paul Drawz, Mahboob Rahman
Journal: Annals of Internal Medicine (2015)

This issue provides a clinical overview of chronic kidney disease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of science writers and physician writers. Editorial consultants from ACP Smart Medicine and MKSAP provide expert review of the content. Readers who are interested in these primary resources for more detail can consult http://smartmedicine.acponline.org, http://mksap.acponline.org, and other resources referenced in each issue of In the Clinic.
Correction
Journal: Circulation (2007)

error appeared on page 2237.In the section "Considerations for Evaluating and Choosing Trans Fatty Acid Alternatives," the second item in the second bulleted list, which appears in the second column, should be changed to the following:In the development of new varieties of oil seeds, long lead time is required.The decision about which specific seeds to grow is made several years in advance of oil delivery; thus, contract planting is necessary.The normal 4-year cycle begins with seed decisions in September of year 1 in anticipation of demand by the food industry in year 4. Seed production contracts are finalized in March of year 2. Farmers are contracted by January of year 3, with the delivery of oils in year 4.However, for seed companies that have ramped up production to address the rapidly growing market demand, the cycle could be shorter, from around 1 year to 20 months.
List of Contributors
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inactivation of the Glycine Transporter 1 Gene Discloses Vital Role of Glial Glycine Uptake in Glycinergic Inhibition
Authors: Jesús Gomeza, Swen Hülsmann, Koji Ohno, Volker Eulenburg, Katalin Szöke, Diethelm Richter, Heinrich Betz
Journal: Neuron (2004)
Phase II Study of thalidomide, Interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC)
Authors: A. Rawat, R. J. Amato
Journal: Journal of Clinical Oncology (2004)

4702 Background: Thalidomide's anti-RCC activity, the potential that its immunomodulatory and anti-angiogenic effects may augment the antitumor activity of IL-2, and the promising early efficacy and safety findings observed with the combination of low dose sc IL-2 plus thalidomide therapy in the treatment of patients with metastatic RCC (ASCO, 2003) form the foundation for the current study. GM-CSF increases the number and activity of macrophages, which may provide a means to enhance the immune system against tumor cells, thus improving the antitumor activity of thalidomide plus IL-2. Methods: Eligibility includes histologic diagnosis of confirmed RCC excluding papillary, sarcomatoid, or collecting duct tumors, measurable disease, normal organ/marrow function, life expectancy >3 months, Zubrod performance status ≤ 2, no prior chemotherapy or immunotherapy, and no active CNS disease. Thalidomide was started at 200 mg after 48 hours to 400 mg at week zero. IL-2 at 7 mIu/m2 and GM-CSF at 250 mcg/m2 were given by subcutaneous injection, starting at week 1, days 1 through 5, weeks 1 through 4, with rest from IL-2 and GM-CSF at weeks 5 and 6. One cycle was 6 weeks. Response was assessed every 2 therapy cycles. 11 patients have been enrolled to date. One patient is inevaluable for response secondary to CNS toxicity and early removal from therapy. Patient characteristics; 11 male, 0 female, aged 57 - 73 (median 64) yrs were included; 11 pts had confirmed RCC. All patients had metastatic disease. Sites included: lung (N=10), nodal (N=3), liver (N=2), bone( N=1). Number of metastatic sites: 1 (N=8), 2 (N=1), 3 (N=2) Zubrod Performance Status: 0 (N= 11). Results: There has been 1 complete response and 9 pts are too early. Toxicities were generally grade 1–2 and included; somnolence, constipation, rash, flu-like symptoms associated with IL-2, fluid retention associated with the combination, hypotension (which was managed with oral fluids), hypothyroidism, sinus bradycardia, and peripheral neuropathy. Conclusions: Enrollment is ongoing, further data regarding response rate, time to progression, and toxicity will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene
Medical malpractice claims filed by Medicaid and non-Medicaid recipients in Maryland
Authors: M. G. Mussman
Journal: JAMA (1991)

Several databases available in Maryland are used to investigate whether Medicaid recipients are more likely than other persons to engage in medical malpractice litigation. All malpractice claims filed during 1985 and 1986 (N = 1037) were updated for outcomes through 1989 and described with regard to the payer status of claimants. The proportion of claims filed by persons enrolled in Medicaid before and/or during the alleged malpractice incident was lower than the proportion of state residents enrolled in Medicaid. In addition, the proportion of obstetric claims filed by Medicaid recipients was identical to their proportion of hospital discharges for obstetric services during the period in which the incidents occurred. (<i>JAMA</i>. 1991;265:2992-2994)
"NONSPLINTING TREATMENT OF FRACTURES OF THE ELBOW JOINT"
Authors: Abraham A. Neuwirth
Journal: JAMA (1942)

<h3>To the Editor:—</h3> In the June 27 issue ofThe Journala communication was published from Dr. D. H. O'Donoghue commenting on my article entitled "Nonsplinting Treatment of Fractures of the Elbow Joint," which appeared in the issue of March 21. The obvious misconception as indicated by the two chief objections to this method of treatment should be clarified. The objections are essentially that the method oversimplifies the treatment of fractures of the elbow and that anatomic reposition should be obtained. The nonsplinting treatment of fractures of the elbow is by no means an oversimplification of treatment. On the contrary, the method involves greater skill, care and time than the usual splinting method. As to the anatomic reposition, it was indicated that in these fractures the fragments are difficult and frequently impossible to realine and that it is even more difficult to hold them in realinement. Fractures with fragments of
SLOW FEVER.
Authors: H. F. HARRIS
Journal: JAMA (1907)

<h3>Synonyms:</h3> Typho-malarial fever; simple continued fever; remittent malaria fever; Willacoochee fever; continued fever; bilious fever; typhoid fever. <h3>Definition:</h3> A continued fever occurring almost exclusively during the warm months and lasting from one to ten weeks. From the above list of names, by which this disease has at times been designated, it will be seen that there has been in the past most divergent views as to its causation and real nature. Many physicians living in the swampy regions of southern Georgia maintain that this affection is but a severe form of malaria, while others of equal capacity and intelligence are quite as positive that it is a mild form of typhoid fever; there are not wanting still others equally as capable who hold that the malady is neither one nor the other, but is a separate and distinct disease. These varying views have been maintained by their several advocates probably
STRICTURE OF THE NASAL DUCT.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Colchicine and disk disease
Authors: M. R. Rask
Journal: JAMA (1986)

<h3>In Reply.—</h3> According to the second reference cited above, the mean concentration of soluble plutonium (<sup>239</sup>Pu) detected at the Maxey Flats site was 0.01 pCi/mL, with a range of 0 to 0.12 pCi/mL (pCi=picocurie=10-<sup>12</sup>curies-0.22 disintegrations per minute).<sup>1</sup>The maximum permissible concentration for soluble<sup>239</sup>Pu is 5 pCi/ mL,<sup>2</sup>500 times the mean concentration found. A subsequent report<sup>3</sup>indicated no off-site migration of plutonium, and an overwhelming percentage of the concentration was in drainage ditches constructed for monitoring purposes and in the top 2 cm of soil, which strongly suggests a surface rather than subsurface vector. As noted in our article, some failures of waste containment have occurred. Extensive study of problems encountered at sites such as Maxey Flats and West Valley, NY, have led to an understanding of why the leakage occurred and also of the means of prevention. Design of any new
LETTER FROM LONDON.
Authors: None G. O. M.
Journal: JAMA (1890)

(FROM OUR REGULAR CORRESPONDENT.) Influenza an old acquaintance in Ireland— Alarms of Cholera—Asepsis of Catheters—Death of Sir William Hoffmeister—Sanitary Condition of Workmen's Dwellings in Liverpool—A New Way of Committing Suicide. Influenza, according to the Irish Local Government Board, is an old acquaintance in Ireland. A passage is quoted from the "Annals of Ulster," A.D. 1326: "Awful thunder and lightning this year which destroyed the corn and produce of Erinn so that it was blanched and waste. An epidemial disease common throughout all Erinn which was called ' Staedan ' (prostration), which affected during three or four days every person so that it was second only to death." In 1328 influenza is recorded under the name of "staedan" in the "Annals of the Four Masters" and in the "Annals of Connaught," and under the name of "Murre" in the "Annals of Clon Machoire." Several outbreaks of influenza are mentioned in the fourteenth century
The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer
Authors: M. J. McFarlane
Journal: JAMA (1987)

When rising rates of occurrence are reported for a particular disease, clinicians often cannot determine whether the disease has increased in actual occurrence or in the improved detection provided by better diagnostic technology and expanded access to medical care. The epidemiologic use of necropsy data, which might help answer these questions, has been inhibited by fears of bias in demographic and clinical selection of patients for necropsy. The demographic problem can be managed by suitable adjustment and standardization of the disease rates found at necropsy, and the clinical problem can be reduced or avoided by studying the rates with which the disease is found unexpectedly in necropsies performed for other, unrelated clinical reasons. The results, obtained in population groups "screened" via necropsy, can suggest the magnitude of the "undetected reservoir" that coexists and supplements the rates of reported occurrence for a disease. In a study of necropsies at Yale—New Haven (Conn) Hospital from 1972 to 1981, the necropsy detection rates for lung cancer were slightly higher for women than for men, and were substantially higher for both genders than the customarily reported rates in the general population. The results suggest that the reported rates may continue to rise in both genders until they become essentially equal at a size approximating that of the currently undetected reservoir. The "epidemiologic necropsy" offers a potentially valuable method to help distinguish the true occurrence rates of disease from the changes attributable to improved diagnostic detection with modern technology. (<i>JAMA</i>1987;258:331-338)
Radiology, Detroit
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drinking, Addiction and Disenchanted Parents Discussed at APHA Meeting
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal